Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Trellus Health PLC ( (GB:TRLS) ) just unveiled an update.
Trellus Health plc announced that all resolutions put to shareholders at its General Meeting on 20 January 2026 were duly passed on a poll, with each motion receiving more than 99.8% of votes cast in favour. The strong shareholder support provides the company with the necessary corporate approvals to continue executing its strategy around its Trellus Elevate® digital platform and broader value-based chronic care offering, reinforcing its operational flexibility and governance backing as it pursues growth in the chronic disease management market.
The most recent analyst rating on (GB:TRLS) stock is a Sell with a £0.38 price target. To see the full list of analyst forecasts on Trellus Health PLC stock, see the GB:TRLS Stock Forecast page.
Spark’s Take on GB:TRLS Stock
According to Spark, TipRanks’ AI Analyst, GB:TRLS is a Neutral.
The score is primarily weighed down by weak financial performance—large ongoing losses and persistent cash burn—despite the benefit of having no debt. Technical signals also remain clearly bearish (below key moving averages with negative momentum), while valuation provides limited support because the company is unprofitable and has no stated dividend yield.
To see Spark’s full report on GB:TRLS stock, click here.
More about Trellus Health PLC
Trellus Health plc is a healthcare company listed on AIM that provides value-based, technology-enabled solutions to help people with complex chronic conditions manage their health through its Trellus Elevate® digital platform. The company integrates proprietary resilience-based methodology, data analytics, expert coaching and education to deliver whole-person condition management, initially focused on high-cost gastrointestinal diseases such as inflammatory bowel disease, and also partners with pharmaceutical companies from clinical trials through to commercialisation.
Average Trading Volume: 546,406
Technical Sentiment Signal: Sell
Current Market Cap: £646K
Find detailed analytics on TRLS stock on TipRanks’ Stock Analysis page.